Author Archives for Adeline Chauvigné

New member | Apersy

26 April 2024

Apersy provide expert advisory services for Commercial Strategy and Market Access to integrate the commercial point of view throughout the... View Article

Apax Partners acquires a majority stake in Porsolt

26 April 2024

Apax Partners, a leading European private equity firm,announced that it has acquired a majority stake in Porsolt, an internationally recognized... View Article

New member | HC NEXT

26 April 2024

Are you having trouble meeting your deadlines or your budget? Trouble to prioritize your project portfolio? Are you looking to... View Article

New member | Patriarche

26 April 2024

Patriarche. Augmented Architecture is a cross-disciplinary architecture group focusing on innovation (500 employees – 10 offices) Patriarche has extensive expertise... View Article

BioMAdvanced Diagnostics received €900k in funding from Bpifrance

26 April 2024

🧪 The “Aide au Développement Deeptech (ADD)” Grant is reserved for startups which develop highly technological innovations. So for BioMAdvanced... View Article

New member | YouCie

26 April 2024

After an overview of the mechanisms of the pharmacy and the problems encountered by the pharmacist and the patient, YouCie... View Article

New member | Abcely

26 April 2024

Abcely’s mission is to develop new innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers,... View Article

XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1 variant

26 April 2024

In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA has just carried out an... View Article

Naobios signs a Research License Agreement with Valneva on EB66® cell line

26 April 2024

Naobios announced the signature of a Research License Agreement with Valneva to assess the EB66® cell line as cell substrate for the evaluation... View Article

OSE Immunotherapeutics receives €10 Million

26 April 2024

This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article